Acutus Medical Achieves Significant Financial Progress in 2024
Acutus Medical, Inc. (OTC: AFIB) recently reported impressive financial results for the year. This California-based medical technology company has demonstrated substantial growth in its revenue and efficiency. In 2024, their revenue from continuing operations reached $20.2 million, marking a remarkable 181% increase from $7.2 million in the previous year. This upward trajectory showcases the company’s resilience and innovative approach in the ever-evolving healthcare landscape.
Key Highlights of the Fiscal Year
Throughout 2024, Acutus has achieved several noteworthy accomplishments:
- The company effectively narrowed its operating loss to $0.1 million compared to an operating loss of $11.7 million in 2023.
- It recorded a gain of $10.8 million from the sale of its business, which reflects a 19% improvement over the prior year.
- As of December 31, 2024, Acutus had cash and cash equivalents totaling $14.0 million, bolstered by their strategic decisions.
Financial Overview for 2024
The gross margin for continuing operations saw a dramatic improvement, reaching 5% for 2024 compared to a staggering negative 44% in 2023. This improvement can be attributed to increased production efficiencies and better management of manufacturing overhead expenses. Operating expenses decreased significantly to $1.1 million in 2024, driven primarily by the reduction of discretionary spending within the new business model established by Acutus.
Despite these positive developments, the net loss for continuing operations amounted to $4.6 million, resulting in a net loss per share of $0.16 based on a weighted average share count of 29.8 million. This reduction in loss from the previous year, where the loss stood at $11.9 million, indicates a turning point for the company.
Loss on Discontinued Operations
Trends in discontinued operations also communicated a more favorable outlook, as the loss decreased to $5.0 million compared to $69.7 million in the prior year. This significant turnaround reflects Acutus's focused strategy in refining its business and capitalizing on profitable segments.
Future Outlook of Acutus Medical
Moving forward, Acutus Medical plans to realign its resources to bolster its left-heart access distribution business and step away from the electrophysiology mapping and ablation sectors. This strategy may lead to a more streamlined and effective operational model, although the company has indicated that it will not provide specific financial guidance moving ahead. The decision to pivot strategically is expected to foster growth in more lucrative areas.
About Acutus Medical
Founded in 2011, Acutus Medical operates with a clear mission: to produce cutting-edge left-heart access products through a distribution agreement with Medtronic, Inc. With its headquarters in Carlsbad, California, Acutus Medical continues to innovate in ways that improve patient outcomes and operational efficiencies.
Frequently Asked Questions
What was Acutus Medical's revenue growth in 2024?
Acutus Medical achieved a revenue growth of 181%, reaching $20.2 million compared to $7.2 million in 2023.
What were the operating losses reported for 2024?
The operating loss for 2024 was reduced to $0.1 million from $11.7 million the previous year.
What is the significance of the gain on sale of the business?
Acutus recorded a $10.8 million gain from the sale, representing a 19% increase over the previous year, enhancing the company's financial stability.
How much cash did Acutus Medical hold at the end of 2024?
As of December 31, 2024, the company had cash, cash equivalents, marketable securities, and restricted cash amounting to $14.0 million.
What is Acutus Medical's strategy going forward?
The company plans to concentrate on its left-heart access distribution business and has decided not to provide financial guidance for future periods.
